查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1840753

僵直性脊椎炎市场按给药途径、患者年龄层、最终用户和给药途径划分 - 全球预测 2025-2032

Ankylosing Spondylitis Market by Administration Route, Patient Age Group, End User, Route Of Administration - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，僵直性脊椎炎市场规模将达到 108.1 亿美元，复合年增长率为 8.56%。

关键市场统计数据
基准年 2024 56亿美元
预计年份：2025年 60.9亿美元
预测年份 2032 108.1亿美元
复合年增长率 (%) 8.56%

针对僵直性脊椎炎的综合临床和系统框架，可以让相关人员以综合的方式考虑治疗和护理服务。

僵直性脊椎炎仍是一种复杂的发炎性疾病，对风湿病学、骨科、復健和卫生经济学都有影响。报告的开篇概述为僵直性脊椎炎的临床表现、不断发展的治疗方法以及不断变化的支付方和医疗服务提供方动态提供了框架，这些因素正在影响着相关人员对诊断、治疗和长期管理的方式。引言部分将近期机制方面的发现与可操作的治疗路径相结合，为临床医生、支付方、製造商和患者权益倡导者制定策略决策奠定了基础。

本书重点阐述了诊断挑战、临床表现的多样性以及对生活品质和功能结局的后续影响。此外，本书也着重介绍了新型生物製药、小分子药物和支持性治疗之间的相互作用，并强调了治疗方法选择越来越受到患者合併症和给药途径等因素的影响。引言部分也重点介绍了数位健康工具和病患报告结局在推动更个人化的医疗服务和支援基于价值的合约讨论中所发挥的作用。本部分从临床背景转向商业性影响，为后续章节对政策、区域动态和细分市场层面的深入分析奠定了基础。

治疗创新、诊断和医疗服务模式的革新如何协同作用，重塑僵直性脊椎炎生态系统中的临床实践、循证需求和支付方预期？

在治疗创新、诊断技术的进步和新型护理模式的推动下，僵直性脊椎炎的治疗和护理模式正在发生显着变革时期。新型标靶治疗和口服小分子药物正在拓展传统生物製药以外的治疗途径，而影像学和生物标记的进步则使得早期诊断更加精准成为可能。这些转变正在改变临床诊疗流程，并提高了人们对长期疾病控制、功能保留和降低併发症负担的期望。

同时，支付方模式和合约方式也在不断演变，以奖励疗效和依从性，这促使製造商重新思考证据生成和患者支持基础设施。数位疗法和远端监测工具的普及为支持长期参与和依从性创造了机会，但也对互通性和数据管治提出了新的要求。因此，成功的相关人员将是那些能够将临床价值提案与实际交付模式相结合、投资于真实世界证据生成并设计差异化病患准入计画的机构。本章将探讨这些变革性趋势如何交织，并概述其对临床开发、商业化和医疗系统整合的策略意义。

关税政策变化对僵直性脊椎炎治疗药物供应链、筹资策略和商业性韧性的实际影响

2025年关税政策调整的累积影响，为生物製药价值链的供应链设计、筹资策略和定价结构带来了新的考量。更高的进口关税和日益复杂的关税体系，凸显了在地化生产决策和分销网络弹性的重要性。製造商和经销商现在必须权衡集中化生产的效率优势与区域或国内产能带来的成本节约之间的利弊。

这些政策发展不仅会影响到岸成本的即时调整，还会影响与医疗体系的合约谈判。由于采购团队会将关税相关的成本差异纳入采购决策，因此与医疗系统和支付方的合约谈判也会受到影响。同时，各公司正在加快制定应急计划，包括策略性储备、多通路采购以及对大宗商品进行选择性区域化，以维持利润率稳定和供应连续性。合规性和海关弹性已成为竞争优势，凸显了商业、供应链和法律团队之间跨职能协调的必要性。展望未来，相关人员，将更有利于进入市场并保持营运韧性。

高解析度細項分析将给药途径、年龄层和最终用户偏好与实际治疗路径和商业优先事项联繫起来。

在僵直性脊椎炎领域，细分市场层面的细微差别是影响临床应用、患者体验和商业化策略的关键因素。根据给药途径，本研究对注射剂、静脉注射剂和口服製剂的市场进行了分析。注射剂又进一步细分为静脉注射剂和皮下注射剂。口服製剂则进一步细分为胶囊剂和锭剂。我们揭示了给药途径如何影响患者依从性、临床监测需求和临床经济效益，其中皮下注射剂的优势在于门诊病人的便利性，而静脉注射剂则更侧重于输注给药。

患者的异质性也会影响需求和治疗路径。根据患者年龄组，市场研究分别针对成人、老年人和儿童。年龄差异会影响合併症情况、安全考量和决策优先事项，并体现在标籤策略和药物流行病学计划中。最终用户动态决定了医疗服务的提供地点和支援服务的建构方式：根据最终用户，市场研究分别针对居家照护中心、医院和专科诊所。每种机构的报销、人员配备和监测能力各不相同，这些都会影响产品定位和服务设计。

最后，我们进一步依给药途径细分。依给药途径，我们考察注射剂、口服剂和局部剂。注射剂进一步细分为静脉注射和皮下注射。口服剂涵盖溶液剂和片剂。局部剂进一步细分为乳膏剂和凝胶剂。这种细緻的框架有助于明确研发优先顺序、定价策略和病患援助计画的设计，使製剂选择与实际使用模式和临床实际情况相符。

制定区域策略，以适应美洲、欧洲、中东和非洲以及亚太地区不同的报销制度、供应链限制和采用模式。

区域动态仍是策略规划的核心，因为临床实务、报销体系和供应链的实际情况在各大全球区域之间存在显着差异。美洲地区继续强调基于价值的合约和整合式医疗路径，并拥有先进的支付方流程，奖励持久疗效和真实世界证据的收集。相较之下，欧洲、中东和非洲的报销和监管环境各不相同，更有利于制定区域性进入策略和协调定价。在亚太地区，一些市场正在经历新治疗方法的快速普及，而另一些市场则面临成本限制，这导致市场准入和规模化发展面临不同的考量。

这些地域差异会影响市场进入顺序、证据累积的优先事项以及合作伙伴的选择。早期聚焦于特定的高价值细分市场通常能够提供可供更广泛的地理推广的验证点。此外，在地化生产、监管协调以及经销伙伴在降低这些地区的关税和物流风险方面发挥着至关重要的作用。因此，针对不同地区量身定制的策略，既要平衡统一的临床价值讯息，又要兼顾区域营运策略，对于在美洲、欧洲、中东和非洲以及亚太地区持续获得市场认可和推广至关重要。

透过证据产生、在地化生产和整合患者支持来定义竞争优势的竞争策略和伙伴关係模式

在僵直性脊椎炎领域，竞争格局日益凸显，整合了治疗效果、病患支持服务和数据主导的证据产生等综合解决方案。以研发为导向的生物製药公司持续投资，透过靶向管线产品和拓展适应症来提升临床差异化；而专科生物製药公司则专注于机制创新和市场定位。同时，口服小分子药物和学名药生产商正利用製剂改进和差异化给药系统来抢占治疗链的各个环节。

整个生态系统内的伙伴关係正在加速发展，製药公司与专业服务供应商携手合作，提供涵盖依从性、监测和疗效评估的综合解决方案。诊断和影像公司正深化与临床相关人员的合作，以支援早期检测和长期疾病管理，而受託製造製造商则在调整生产模式，以满足对本地化生产能力的需求。总而言之，这些公司层面的趋势意味着，策略联盟、灵活的生产模式以及强大的真实世界证据能力将决定谁能够持续创造临床和商业性价值。

一套切实可行的策略方案，旨在透过证据产生、供应链灵活性和以患者为中心的交付方式，获取治疗和商业性价值。

产业领导者应优先采取一系列切实可行的措施，使临床差异化与商业性可行性和营运韧性一致。首先，投资整合证据计划，结合随机对照试验、真实世界临床试验和病患报告结局，向支付者和临床医生证明其长期价值。其次，重新思考供应链布局，在集中效率和区域弹性之间取得平衡，以因应关税变化和采购差异。第三，设计以病人为中心的交付模式，考虑给药途径偏好和临床试验中心的经济效益，从而兼顾依从性和成本效益。

此外，我们将加强与诊断、数位医疗和专科护理网络之间的策略伙伴关係，以推进早期诊断和持续疾病监测。我们将实施灵活的合约选项和风险分担机制，使其与当地的医保报销政策相符，从而加快市场准入并降低支付方的阻力。最后，我们将优先发展数据分析和监管事务的能力，将真实世界的洞察转化为扩大适应症范围和差异化报销的讨论。这些措施将有助于把临床创新转化为以患者为中心、永续的商业性成果。

采用透明的多方法研究途径，结合一手访谈、二手文献综合和三角验证分析，确保获得可靠的策略洞察。

本报告的调查方法结合了质性研究、严谨的二手资料和结构化资料综合，以确保结论的可重复性和可操作性。定性研究包括对临床医生、医保专家、供应链高管和患者权益倡导代表进行深度访谈，以深入了解治疗模式、就医障碍和实际治疗偏好。这些访谈旨在揭示营运中的细微差别，并检验假设驱动的分析框架。

二次研究透过整合同行评审文献、监管指南、临床实践建议和公开的卫生系统报告，对主要研究结果进行了补充。研究采用资料三角测量技术，协调不同资讯来源的观点，并增强解释的可靠性。透过反覆的同侪审查、方法透明化以及对资讯来源和解释的品质检查，确保了分析方法的严谨性。在适用情况下，研究也运用了敏感度分析和情境规划，以检验策略影响的稳健性，并为临床、商业和政策领域的相关人员提供更灵活的建议。

整合临床、商业性和营运方面的必要因素，领导者必须协调一致，才能将治疗进展转化为持续的患者和系统层面的价值。

总而言之，僵直性脊椎炎领域呈现出临床创新、不断演进的护理模式以及营运压力并存的特点，这既为相关人员带来了机会，也带来了挑战。治疗方法多样化、诊断技术的进步以及数位医疗的整合正在重塑患者的诊断和管理方式，而支付方和采购机制的变化则要求更精细的价值沟通和更具适应性的供应策略。给药途径、患者族群特征和治疗环境之间的相互作用，进一步影响治疗在何处以及如何真正发挥临床疗效。

策略成功取决于将实证实践与务实的商业化策略相结合，投资于灵活的生产和分销，并建立超越传统产品中心模式的伙伴关係。专注于病患疗效、在地化特色和灵活的营运设计，有助于机构克服政策变革和推广应用方面的障碍，同时提供更优质的医疗服务。结论强调，需要采取审慎且全面的方法，将科学进步转化为持久的患者获益和永续的商业性绩效。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 白细胞介素-17抑制剂的出现，提高了僵直性脊椎炎。
  • 生物相似药肿瘤坏死因子抑制剂的快速上市降低了治疗成本，并提高了僵直性脊椎炎患者获得治疗的机会。
  • 整合远端医疗和远端患者监护平台，以提高僵直性脊椎炎临床管理中的依从性和早期病情復发检测。
  • 透过基于HLA-B27基因分型和生物标记分析的个人化治疗流程的进步，实现标靶治疗
  • 增加对JAK抑制剂治疗僵直性脊椎炎的投资，并评估其与生物製药相比的长期安全性
  • 利用病患登记的真实世界证据，了解新治疗方法的长期疗效和安全性。
  • 扩大支付方和生产商之间基于价值的合约模式，以优化结果并控製成本。
  • 一项新研究探讨了肠道菌丛调节作为控制发炎的新治疗方法。
  • 开发数位化物理治疗和运动指导应用程序，以提高患者参与度和改善护理中的功能性结果。
  • 新一代小分子抑制剂获得监管部门核准，拓宽了难治性僵直性脊椎炎的治疗前景

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章僵直性脊椎炎市场（依给药途径划分）

  • 注射
    • 静脉输液
    • 皮下注射
  • 静脉
  • 口服
    • 胶囊
    • 药片

第九章 依患者年龄层分類的僵直性脊椎炎市场

  • 成人版
  • 老年人
  • 孩子们

第十章僵直性脊椎炎市场（依最终用户划分）

  • 居家护理中心
  • 医院
  • 专科诊所

第十一章僵直性脊椎炎市场（依给药途径划分）

  • 注射
    • 静脉输液
    • 皮下注射
  • 口服
    • 解决方案
    • 药片
  • 话题
    • 奶油
    • 凝胶

第十二章僵直性脊椎炎市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章僵直性脊椎炎市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国僵直性脊椎炎市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • AbbVie Inc.
    • Novartis AG
    • Pfizer Inc.
    • Amgen Inc.
    • Eli Lilly and Company
    • Galapagos NV
    • Gilead Sciences, Inc.
    • Sandoz International GmbH
Product Code: MRR-A339DAEFAA9A

The Ankylosing Spondylitis Market is projected to grow by USD 10.81 billion at a CAGR of 8.56% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.60 billion
Estimated Year [2025] USD 6.09 billion
Forecast Year [2032] USD 10.81 billion
CAGR (%) 8.56%

Comprehensive clinical and systemic framing of ankylosing spondylitis to orient stakeholders toward integrated therapeutic and care-delivery considerations

Ankylosing spondylitis remains a complex inflammatory condition with implications across rheumatology, orthopedics, rehabilitation, and health economics. This report's opening synthesis frames the clinical profile, evolving therapeutic approaches, and the shifting payer and care-delivery dynamics that shape how stakeholders approach diagnosis, treatment, and long-term management. By situating recent mechanistic discoveries alongside pragmatic treatment pathways, the introduction sets a foundation for strategic decisions by clinicians, payers, manufacturers, and patient advocates.

The narrative emphasizes diagnostic challenges, the heterogeneity of clinical presentation, and the downstream effects on quality of life and functional outcomes. It also foregrounds the interplay between novel biologics, small molecules, and supportive care modalities, highlighting how therapeutic selection increasingly depends on patient comorbidities and route-of-administration considerations. Furthermore, the introduction underscores the role of digital health tools and patient-reported outcomes in driving more personalized care and in supporting value-based contracting discussions. Transitioning from clinical context to commercial implications, this section prepares readers for deeper analysis of policy, regional dynamics, and segment-level insights that follow in subsequent chapters.

How therapeutic innovation, diagnostics, and care-delivery redesign are jointly reshaping clinical practice, evidence needs, and payer expectations across the ankylosing spondylitis ecosystem

The treatment and care landscape for ankylosing spondylitis is undergoing a period of substantive transformation driven by therapeutic innovation, enhanced diagnostics, and new care models. Emerging targeted agents and oral small molecules are expanding the armamentarium beyond traditional biologic classes, while advances in imaging and biomarkers are enabling earlier and more precise diagnosis. These shifts are altering clinical algorithms and increasing expectations for sustained disease control, functional preservation, and reduced comorbidity burden.

Concurrently, payer models and contracting approaches are evolving to reward outcomes and adherence, prompting manufacturers to rethink evidence generation and patient-support infrastructures. Digital therapeutics and remote monitoring tools are gaining traction, creating opportunities for long-term engagement and adherence support but also placing new demands on interoperability and data governance. As a result, successful stakeholders are those aligning clinical value propositions with pragmatic delivery models, investing in real-world evidence generation, and designing differentiated patient access programs. This chapter explores how these transformative currents intersect, and it outlines the strategic implications for clinical development, commercialization, and health-system integration.

Practical implications of tariff policy changes on supply chains, procurement strategies, and commercial resilience for ankylosing spondylitis therapies

The cumulative effects of tariff policy shifts in 2025 introduced new considerations for supply chain design, procurement strategies, and pricing architecture across the biopharmaceutical value chain. Increased import duties and tariff complexity have elevated the importance of local manufacturing footprint decisions and the flexibility of distribution networks. Manufacturers and distributors must now weigh the trade-offs between centralized production efficiencies and the cost mitigation benefits of regional or in-country production capabilities.

These policy developments have implications beyond immediate landed cost adjustments. They affect contractual negotiations with health systems and payers, as procurement teams integrate tariff-related cost variability into sourcing decisions. In parallel, companies are accelerating contingency planning to preserve margin stability and continuity of supply, including strategic stockpiling, multi-sourcing, and selective regionalization of high-volume product lines. Regulatory compliance and customs agility have become competitive differentiators, underscoring the need for cross-functional coordination between commercial, supply chain, and legal teams. Moving forward, stakeholders that proactively model tariff exposure and embed flexible manufacturing and distribution options into their commercial playbooks will be better positioned to sustain market access and operational resilience.

High-resolution segmentation analysis linking administration route, age cohorts, and end-user settings to real-world treatment pathways and commercial priorities

Segment-level nuance is a critical determinant of clinical adoption, patient experience, and commercialization strategy in ankylosing spondylitis. Based on Administration Route, market is studied across Injectable, Intravenous, and Oral. The Injectable is further studied across Intravenous Infusion and Subcutaneous Injection. The Oral is further studied across Capsules and Tablets. This perspective clarifies how route of administration influences adherence patterns, clinical monitoring needs, and site-of-care economics, with subcutaneous formulations offering outpatient convenience and intravenous options concentrated in infusion settings.

Patient heterogeneity also shapes demand and care pathways; based on Patient Age Group, market is studied across Adult, Geriatric, and Pediatric. Age-related differences affect comorbidity profiles, safety considerations, and shared decision-making priorities, thereby informing label strategies and pharmacoepidemiology plans. End-user dynamics determine where care is delivered and how support services are structured: based on End User, market is studied across Homecare Centers, Hospitals, and Specialty Clinics. Each setting has distinct reimbursement, staffing, and monitoring capabilities that influence product positioning and services design.

Finally, route-specific segmentation is further refined: based on Route Of Administration, market is studied across Injectable, Oral, and Topical. The Injectable is further studied across Intravenous Infusion and Subcutaneous Injection. The Oral is further studied across Solutions and Tablets. The Topical is further studied across Creams and Gels. This granular framework helps clarify R&D prioritization, pricing strategy, and patient support program design by aligning formulation choices with real-world use patterns and site-of-care realities.

Regionally calibrated strategies to reconcile divergent reimbursement systems, supply-chain constraints, and adoption patterns across the Americas, EMEA, and Asia-Pacific

Regional dynamics remain central to strategic planning, as clinical practice, reimbursement frameworks, and supply-chain realities vary significantly across major world regions. The Americas continue to demonstrate a strong emphasis on value-based contracting and integrated care pathways, with advanced payer processes that incentivize durable outcomes and real-world evidence collection. In contrast, Europe, Middle East & Africa show heterogeneous reimbursement landscapes and regulatory approaches that favor region-specific access strategies and collaborative pricing arrangements. Asia-Pacific presents rapid uptake of new modalities in some markets alongside cost-constrained environments in others, creating a diverse set of market-entry and scale-up considerations.

These geographic differences affect go-to-market sequencing, evidence-generation priorities, and partner selection. In many cases, early commercial focus on specific high-value submarkets enables proof points that can be adapted for broader regional rollout. Moreover, local manufacturing, regulatory harmonization efforts, and distribution partnerships play pivotal roles in mitigating tariff and logistic exposure across these regions. Accordingly, a regionally calibrated approach that balances uniformity of clinical value messaging with localized operational tactics will be essential for sustained access and uptake across the Americas, Europe, Middle East & Africa, and Asia-Pacific.

Corporate strategies and partnership models that are defining competitive advantage through evidence generation, localized manufacturing, and integrated patient support

Competitive dynamics in ankylosing spondylitis are increasingly defined by integrated offerings that combine therapeutic efficacy with patient support services and data-driven evidence generation. Established biopharmaceutical firms continue to invest in clinical differentiation through targeted pipeline assets and extended indication development, while specialty biotech companies focus on mechanistic innovation and niche positioning. Concurrently, manufacturers of oral small molecules and generics are leveraging formulation improvements and differentiated delivery systems to capture segments of the treatment continuum.

Partnerships across the ecosystem are accelerating, with collaborations between pharma companies and specialty service providers enabling bundled solutions that address adherence, monitoring, and outcomes measurement. Diagnostics and imaging firms are deepening engagement with clinical stakeholders to support earlier detection and longitudinal disease management, and contract manufacturing organizations are adapting to demand for more localized production capacity. Collectively, these company-level trends point toward a landscape where strategic alliances, flexible manufacturing models, and robust real-world evidence capabilities determine who can deliver sustained clinical and commercial value.

Actionable strategic playbook for aligning evidence generation, supply-chain flexibility, and patient-centric delivery to capture therapeutic and commercial value

Industry leaders should prioritize a set of actionable measures that align clinical differentiation with commercial viability and operational resilience. First, invest in integrated evidence plans that combine randomized trials, pragmatic real-world studies, and patient-reported outcomes to substantiate long-term value for payers and clinicians. Second, reassess supply-chain footprints to balance centralized efficiencies with regional agility, enabling responsiveness to tariff shifts and procurement variability. Third, design patient-centric delivery models that account for administration-route preferences and site-of-care economics, supporting both adherence and cost-effectiveness.

In addition, cultivate strategic partnerships across diagnostics, digital health, and specialty care networks to accelerate early diagnosis and continuous disease monitoring. Embed flexible contracting options and risk-sharing arrangements tailored to regional reimbursement realities to facilitate market access and reduce payer resistance. Finally, prioritize capability-building in data analytics and regulatory affairs to translate real-world insights into label expansions and differentiated reimbursement conversations. Collectively, these actions will enable organizations to convert clinical innovation into sustainable, patient-centered commercial outcomes.

Transparent, multi-method research approach combining primary interviews, secondary literature synthesis, and triangulated analysis to ensure credible strategic insights

The research methodology underpinning this report combines primary qualitative inquiry with rigorous secondary intelligence and structured data synthesis to ensure reproducibility and actionable clarity. Primary research involved in-depth interviews with clinicians, reimbursement specialists, supply-chain executives, and patient advocacy representatives to capture practical insights on care patterns, access barriers, and real-world treatment preferences. These conversations were designed to illuminate operational nuances and to validate hypothesis-driven analytic frameworks.

Secondary research complemented primary findings by consolidating peer-reviewed literature, regulatory guidance, clinical practice recommendations, and publicly available health-system reports. Data triangulation techniques were applied to reconcile differing source perspectives and to strengthen the reliability of interpretation. Analytic rigor was maintained through iterative peer review, methodological transparency, and quality checks on sourcing and interpretation. Where applicable, sensitivity analysis and scenario planning were used to test the robustness of strategic implications, supporting more resilient recommendations for stakeholders across clinical, commercial, and policy domains.

Synthesis of clinical, commercial, and operational imperatives that leaders must align to translate therapeutic progress into durable patient and system-level value

In sum, the ankylosing spondylitis landscape is characterized by clinical innovation, evolving care models, and operational pressures that together create both opportunity and complexity for stakeholders. Therapeutic diversification, enhanced diagnostics, and digital health integration are reshaping how patients are diagnosed and managed, while payer and procurement dynamics necessitate more sophisticated value communication and adaptive supply strategies. The interplay between administration routes, patient demographics, and care settings further refines where and how treatments will achieve meaningful clinical impact.

Strategic success will depend on aligning evidence-generation efforts with pragmatic commercialization tactics, investing in flexible manufacturing and distribution, and building partnerships that extend beyond traditional product-centric models. By focusing on patient outcomes, regional particularities, and resilient operational design, organizations can navigate policy shifts and adoption hurdles while delivering improved care. The conclusion emphasizes that deliberate, integrated approaches will be required to translate scientific progress into lasting patient benefit and sustainable commercial performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of interleukin-17 inhibitors showing enhanced symptom control and reduced radiographic progression in ankylosing spondylitis patients
  • 5.2. Rapid adoption of biosimilar tumor necrosis factor blockers driving cost savings and increased patient access to ankylosing spondylitis therapies
  • 5.3. Integration of telemedicine and remote patient monitoring platforms to improve adherence and early flare detection in AS clinical management
  • 5.4. Advances in personalized treatment algorithms guided by HLA-B27 genotyping and biomarker profiling for targeted ankylosing spondylitis care
  • 5.5. Growing investment in JAK inhibitors for ankylosing spondylitis and evaluation of their long term safety compared to biologics
  • 5.6. Utilization of real world evidence from patient registries to inform long term efficacy and safety profiles of emerging ankylosing spondylitis therapies
  • 5.7. Expansion of value based contracting models between payers and manufacturers to optimize outcomes and control costs in ankylosing spondylitis treatment
  • 5.8. Emerging research into gut microbiome modulation as a novel therapeutic approach for inflammation control in ankylosing spondylitis
  • 5.9. Development of digital physiotherapy and exercise coaching apps to enhance patient engagement and functional outcomes in ankylosing spondylitis care
  • 5.10. Regulatory approvals of next generation small molecule inhibitors broadening the treatment landscape for refractory ankylosing spondylitis cases

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Ankylosing Spondylitis Market, by Administration Route

  • 8.1. Injectable
    • 8.1.1. Intravenous Infusion
    • 8.1.2. Subcutaneous Injection
  • 8.2. Intravenous
  • 8.3. Oral
    • 8.3.1. Capsules
    • 8.3.2. Tablets

9. Ankylosing Spondylitis Market, by Patient Age Group

  • 9.1. Adult
  • 9.2. Geriatric
  • 9.3. Pediatric

10. Ankylosing Spondylitis Market, by End User

  • 10.1. Homecare Centers
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Ankylosing Spondylitis Market, by Route Of Administration

  • 11.1. Injectable
    • 11.1.1. Intravenous Infusion
    • 11.1.2. Subcutaneous Injection
  • 11.2. Oral
    • 11.2.1. Solutions
    • 11.2.2. Tablets
  • 11.3. Topical
    • 11.3.1. Creams
    • 11.3.2. Gels

12. Ankylosing Spondylitis Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Ankylosing Spondylitis Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Ankylosing Spondylitis Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. AbbVie Inc.
    • 15.3.2. Novartis AG
    • 15.3.3. Pfizer Inc.
    • 15.3.4. Amgen Inc.
    • 15.3.5. Eli Lilly and Company
    • 15.3.6. Galapagos NV
    • 15.3.7. Gilead Sciences, Inc.
    • 15.3.8. Sandoz International GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ANKYLOSING SPONDYLITIS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ANKYLOSING SPONDYLITIS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANKYLOSING SPONDYLITIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOMECARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOMECARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOMECARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOMECARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOMECARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOMECARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SOLUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SOLUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SOLUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SOLUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SOLUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CREAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CREAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CREAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CREAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CREAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 262. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 277. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 280. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 281. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 282. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 283. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 284. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 285. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 293. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 294. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 312. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 313. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 314. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 315. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 316. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 317. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 318. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 319. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 320. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 321. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 322. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 323. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 324. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 325. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 326. ASEAN ANKYLOSING SPONDYLIT